MedPath

KINIKSA PHARMACEUTICALS (UK), LTD.

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:1
Phase 3:1

Drug Approvals

2

NMPA:1
FDA:1

Drug Approvals

Rilonacept for injection

Product Name
炎朵
Approval Number
国药准字SJ20240045
Approval Date
Nov 22, 2024
NMPA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 3
1 (50.0%)

A Pilot Study of KPL-914 in Recurrent Pericarditis

Phase 2
Completed
Conditions
Recurrent Pericarditis
Interventions
First Posted Date
2019-06-10
Last Posted Date
2021-05-27
Lead Sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Target Recruit Count
26
Registration Number
NCT03980522
Locations
🇺🇸

Medstar Washington Hospital Center, Washington, District of Columbia, United States

🇺🇸

Avail Clinical Research, LLC, DeLand, Florida, United States

🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

and more 11 locations

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Phase 3
Completed
Conditions
Recurrent Pericarditis
Interventions
Drug: Placebo
First Posted Date
2018-11-09
Last Posted Date
2023-09-06
Lead Sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Target Recruit Count
86
Registration Number
NCT03737110
Locations
🇺🇸

Cedars-Sinai Medical Institute, Los Angeles, California, United States

🇺🇸

Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States

🇺🇸

The Loretto Hospital, Chicago, Illinois, United States

and more 18 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.